Biogen

Biogen

About Biogen

Simplify's Rating
Why Biogen is rated
B
Rated A on Competitive Edge
Rated B on Growth Potential
Rated C on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

1978

Overview

Simplify Jobs

Simplify's Take

What believers are saying

  • Biogen's collaboration with Sage Therapeutics could enhance its mental health portfolio.
  • Biogen's new Boston headquarters will consolidate R&D and commercial operations by 2028.
  • Biogen's investment in biosimilars offers market expansion opportunities with cost-effective alternatives.

What critics are saying

  • Increased competition from Eli Lilly's donanemab in Alzheimer's treatment market.
  • High costs of drug development and marketing could strain Biogen financially.
  • Litigation risks in the biosimilar market could impact Biogen's operations.

What makes Biogen unique

  • Biogen's Leqembi is the only FDA-approved anti-amyloid therapy for Alzheimer's.
  • Biogen's investment in gene therapy targets neuromuscular disorders, aligning with personalized medicine trends.
  • Biogen's focus on sustainability enhances its brand reputation among eco-conscious investors.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$2.1M

Above

Industry Average

Funded Over

1 Rounds

Grant funding comparison data is currently unavailable. We're working to provide this information soon!
Grant Funding Comparison
Coming Soon

Benefits

Remote Work Options

Professional Development Budget

Company News

Pharmaceutical Technology
Apr 2nd, 2025
Organon acquires Actemra biosimilar's US rights from Biogen

Organon acquires Actemra biosimilar's US rights from Biogen.

Endpoints News
Mar 24th, 2025
Biogen plans to open new headquarters in Boston area in 2028

Biogen announced on Monday its plans to launch a new headquarters outside Boston, aiming to consolidate its research and development teams alongside its commercial operations...

MarketBeat
Mar 11th, 2025
Generali Investments CEE investicni spolecnost a.s. Invests $4.14 Million in Biogen Inc. (NASDAQ:BIIB)

Generali Investments CEE investicni spolecnost a.s. Invests $4.14 Million in Biogen Inc. (NASDAQ:BIIB).

Biogen
Feb 24th, 2025
Biogen to Participate in the TD Cowen 45th Annual Health Care Conference

Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that Christopher A. Viehbacher, President and Chief Executive Officer, will participate in a fireside chat during the TD Cowen 45th Annual Health Care Conference.

Stock Target Advisor
Feb 18th, 2025
Biogen Inc: AI-Powered "Top Pick" with 63% Upside Forecasted

Biogen Inc. has been determined as a "Top Pick" in the biopharma sector due to its strong financial fundamentals, strategic positioning, and promising growth prospects.

Recently Posted Jobs

Sign up to get curated job recommendations

Director – Msat

Remote in USA

Executive Director - Medical Affairs - Regional Head

Remote in USA

Biogen is Hiring for 2 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Biogen's jobs every few hours, so check again soon! Browse all jobs →

Executive Director - Medical Affairs - Regional Head

Remote in USA

See All Jobs

Biogen is Hiring for 2 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Biogen's jobs every few hours, so check again soon! Browse all jobs →